At a glance
ClinicalIndex Comparison RecordN/ACompleted· 426 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Amevive Wisdom Acquired From Real-Time Evidence (A.W.A.R.E™) Program
In Brief
An observational study for Plaque Psoriasis. Completed, enrolled 426 participants across 30 sites.
Detailed Summary
Purpose: To develop a real time national clinical database to support and share best practices, 1. To generate hypotheses for future clinical research 2. To understand how AMEVIVE is used in routine clinical practice/real world setting. Each patient visit will include the following observational endpoints: 1. AMEVIVE dosing 2. Number of courses 3. Concomitant treatment 4. Response to treatment (patient and physician global assessments) 5. Status of other psoriasis-related medical conditions 6. Time to re-treatment.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
CountriesCanada
Collaborators--
Timeline
N/ACompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2005
First PostedSep 2006
Primary CompletionMay 2008
TodayJul 2026
First PostedSep 4, 2006
Enrollment StartJun 1, 2005
Primary CompletionMay 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 19.8 years ago